"What is discussed at IMPAKT can directly lead to new ways of designing trials that would hopefully lead to new protocols in the course of the next few years and could change outcome for patients."
Andrew Tutt and Peter Dubsky, IMPAKT 2013 Co-Chairs
IMPAKT 2013 will build on topics discussed in previous years and will focus specifically on the following areas - Watch the video here[http://www.
- Breast cancer heterogeneity - Mechanisms, capturing, and clinical implications
- How much is there at the start and how much happens over time
- Can host immune response beat tumour heterogeneity or does it complicate outcomes?
- Dissemination and organ specific metastasis of breast cancer: How does heterogeneity play a role?
- Can heterogeneity in advanced breast cancer be captured by molecular imaging?
- Targeting the PI3K/AKT/mTOR axes in breast cancer: targets, trials and biomarkers
- Cancer reprogramming induced by treatment: Is it a problem and can we predict and inhibit it in the clinic?
- Biomarker driven neoadjuvant trials in breast cancer
- How to avoid false positive and false negative results in the assessment of oestrogen and progesterone receptor status
- In a world of breast cancer heterogeneity is the biopsy of metastasis helpful or distracting?
- Integrating breast cancer genomics and proteomics - shooting for the moon
The full conference programme is available at http://www.
The 2013 Press Programme will capture the very essence of the IMPAKT conference, where the ultimate goal is to improve breast cancer outcome through translational research, i.e. new techniques, new concepts on the cutting edge to change the clinic as soon as possible:
- Biomarker data - including
- Predicting risk for late metastasis: the PMA50 risk of recurrence (ROR) score after 5 years of endocrine therapy in postmenopausal women with HR+ early breast cancer: a study on 1,478 patients from the ABCSG-8 trial (53 O)
- Prognostic and predictive value of IHC4 and ERB1 in the integroup exemestane study (IES) on behalf of the pathies investigators (55 O)
- Comparison of five different scores for the prediction of late recurrence for oestrogen receptor positive breast cancer (54 O)
- Predictive value of AKT/mTOR pathway immunohistochemical (IHC) biomarkers for response to pre-operative trastuzumab vs. trastuzumab + everolimus in patients with early breast cancer: UNICANCER RADHER trial results (56 O)
- Heterogeneity of breast cancer - including
- Contribution of analytical, pre-analytical and intra-tumoral heterogeneity to variance in gene expression measurements from human breast cancers (40 O)
- Heterogeneity of genomic signatures in breast cancer core biopsy (41 O)
- Assessment of Genetic Alterations in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer From the BOLERO-2 Trial by Next-Generation Sequencing (42 O)
Thursday, 2 May 2013, 10:45-11:45 (CEST)
Hosts: Martine Piccart, Jules Bordet Institute, Head of Chemotherapy Unit, Brussels, Belgium, IMPAKT Co-Founder Peter Dubsky, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, Austria, IMPAKT2013 Scientific Chair Andrew Tutt, King's College London Guy's Hospital, London, United Kingdom, IMPAKT2013 Executive Chair
BIG and ESMO welcome media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the Media Policy < http://www.
Please contact the IMPAKT Press Office at email@example.com to request press releases, schedule remote interviews or register for the event. < http://www.
Abstracts accepted for poster presentation and for publication in the IMPAKT Abstract book will be made public online on Monday, 22 April 2013 and will be accessible at http://www.
Abstracts accepted for oral presentation and abstracts selected for the official IMPAKT Press Programme will be embargoed until the official opening of the IMPAKT 2013 Conference, Thursday, 2 May 2013, 12:00 (CEST)
Journalists are required to observe embargoes as indicated, thank you!
Around 500 attendees are expected from throughout Europe and the rest of the world.
The IMPAKT Breast Cancer Conference is an initiative by the Breast International Group (BIG) and the European Society for Medical Oncology (ESMO), in collaboration with the St. Gallen Primary Therapy of Early Breast Cancer Conference, The European Organisation for Research and Treatment of Cancer Breast Cancer Group, The European Society of Breast Cancer Specialists, and Europa Donna - the European Breast Cancer Coalition.
For further information please contact:
IMPAKT Press Office
c/o European Society for Medical Oncology